We are live on ! Find out more
RCUS icon

Arcus Biosciences

15.62 USD
-0.16
1.01%
At close Updated Nov 20, 4:00 PM EST
Pre-market
After hours
15.50
-0.12
0.77%
1 day
-1.01%
5 days
-11.45%
1 month
-34.23%
3 months
-47.09%
6 months
-34.2%
Year to date
-32.93%
1 year
-26.42%
5 years
-67.52%
10 years
-8.12%
 

About: Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.

Employees: 601

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 10%
Neutral 80%
Negative 10%
Neutral
Business Wire
2 days ago
Arcus Biosciences to Participate in Two Upcoming Investor Conferences
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and immune diseases, announced that its management team will participate in the following upcoming investor conferences in December: 8th Annual Evercore Healthcare Conference Date: Tuesday, December 1st, 2026 Location: Coral Gables, FL Format: Fireside chat & 1x1 meetings Time: 3:50.
Arcus Biosciences to Participate in Two Upcoming Investor Conferences
Negative
Zacks Investment Research
16 days ago
Arcus Biosciences, Inc. (RCUS) Reports Q3 Loss, Lags Revenue Estimates
Arcus Biosciences, Inc. (RCUS) came out with a quarterly loss of $1 per share versus the Zacks Consensus Estimate of a loss of $0.92. This compares to a loss of $1.27 per share a year ago.
Arcus Biosciences, Inc. (RCUS) Reports Q3 Loss, Lags Revenue Estimates
Neutral
Business Wire
16 days ago
Arcus Biosciences Reports Third-Quarter 2026 Financial Results and Provides a Pipeline Update
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cancer and immune diseases, today reported financial results for the third quarter ended September 30, 2026, and provided a pipeline update on its clinical-stage investigational molecules and discovery programs. “In October, we showed for the first time that robust and durable HIF-2.
Arcus Biosciences Reports Third-Quarter 2026 Financial Results and Provides a Pipeline Update
Neutral
Business Wire
18 days ago
Arcus Biosciences to Participate in the Jefferies Global Healthcare Conference 2026 in London
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cancer and immune diseases, announced that its management team will participate in a fireside chat at the upcoming Jefferies Global Healthcare Conference in London, UK. The fireside chat will take place on Monday, November 16th, 2026, at 5:00pm GMT. A live webcast of the presentation will.
Arcus Biosciences to Participate in the Jefferies Global Healthcare Conference 2026 in London
Neutral
Business Wire
25 days ago
Arcus Biosciences Announces New Employment Inducement Grants
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cancer and immune diseases, today announced that the Compensation Committee of the Company's Board of Directors granted three new employees options to purchase a total of 10,650 shares of the Company's common stock at an exercise price per share of $18.54, which was the closing price.
Arcus Biosciences Announces New Employment Inducement Grants
Neutral
Business Wire
1 month ago
Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE: RCUS), a late clinical-stage biopharmaceutical company focused on developing differentiated molecules and combinations for the treatment of cancer and immune diseases, today announced the pricing of an underwritten public offering of 14,285,715 shares of its common stock at a price to the public of $17.50 per share. Gross proceeds to Arcus Biosciences from the offering are expected to be $250.0 million, before deducting underwriti.
Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock
Neutral
PRNewsWire
1 month ago
Kuehn Law Encourages Investors of Arcus Biosciences, Inc. to Contact Law Firm
NEW YORK, Oct. 21, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Arcus Biosciences, Inc. ( NYSE : RCUS) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.
Kuehn Law Encourages Investors of Arcus Biosciences, Inc. to Contact Law Firm
Neutral
Business Wire
1 month ago
Arcus Biosciences Announces Commencement of Public Offering of Common Stock
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE: RCUS), a late clinical-stage biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cancer and immune diseases, today announced that it has commenced an underwritten public offering of its common stock. All of the shares of common stock are being offered by Arcus Biosciences. In addition, Arcus Biosciences intends to grant the underwriters a 30-day option to purchase.
Arcus Biosciences Announces Commencement of Public Offering of Common Stock
Positive
Seeking Alpha
1 month ago
Arcus Biosciences: Encouraging Casdatifan Data, But The Hard Part Still Ahead
Arcus Biosciences presented promising ARC-20 platform data for casdatifan across first-line, second-line, and late-line clear cell renal cell carcinoma settings. RCUS's casdatifan combinations showed superior or competitive PFS and response rates versus historical benchmarks, with manageable safety profiles and broad potential across treatment lines. Valuation is rich at 22.5x trailing and 37.9x forward sales, reflecting high pipeline expectations and leaving RCUS vulnerable to clinical setbacks.
Arcus Biosciences: Encouraging Casdatifan Data, But The Hard Part Still Ahead
Positive
MarketBeat
1 month ago
Arcus Biosciences Sees $5B-$10B RCC Opportunity for Casdatifan at Investor Day
Arcus Biosciences NYSE: RCUS presented updated clinical and translational data for casdatifan, its investigational HIF-2 alpha inhibitor, outlining development plans across first-line, second-line and later-line clear cell renal cell carcinoma (RCC).
Arcus Biosciences Sees $5B-$10B RCC Opportunity for Casdatifan at Investor Day
Price charts implemented using Lightweight Charts™